Chamath Palihapitiya says, ‘Rona what?
In an otherwise gloomy day of non-stop Coronavirus news and market oscillation, we did have the Friday gift of not one, but TWO new IPO filings from Social Capital Hedosophia. If you haven’t seen it yet, Social Capital Hedosophia II & III just filed to IPO, with a $300 million and $600 million offering each. Both are 1/4 warrant structures (naturally), and are being underwritten once again by Credit Suisse.
Basically, Chamath just pulled a Triple Lindy and all without wearing a face mask. Social Capital II will be $300 million, while Social Capital III will be $600 million in size, so clearly they will be looking at different target universes. This is a bright spot in an otherwise muted week and sure to get some press coverage. I’ll be reviewing each of the prospectuses and will provide additional commentary next week.
For now, this is the extra lime in your Friday Happy Hour cocktail. Stay tuned…
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...